《公司业绩》中国生物制药(01177.HK)首三季纯利18.5亿人币跌18% 季息2港仙
中国生物制药(01177.HK)公布截至今年9月底止首三季业绩,营业额181.26亿元人民币(下同),按年跌6.2%。纯利18.5亿元,按年跌18%;每股盈利9.81分。派季度息2港仙。期内基本盈利为22.94亿元,按年下跌11.7%。
期内新产品销售收入占集团总收入约36.7%,达到约66.59亿元,较去年同期上升约66.9%;创新药销售额占集团总收入约25%,去年同期占比为约20%。
单计第三季,集团获得临床批件6件、生产批件11件及一致性评价获批15个、申报临床6件、一致性评价申报6个及申报生产2个。已累计有临床批件、正在进行临床试验和申报生产的在研产品共398件,其中肝病用药37件、抗肿瘤用药190件、呼吸系统用药22件、内分泌用药20件、心脑血管用药16件及其它类用药113件。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.